The global focal segmental glomerulosclerosis (FSGS) therapeutics market is on track to achieve remarkable growth, with projections indicating a market value of USD 4.89 billion by 2033, up from USD 3 billion in 2023. This expansion represents a CAGR of 5% from 2023 to 2033, reflecting the growing demand for effective treatment solutions for this rare kidney disorder.
The historical data showcases steady growth, with the market registering a CAGR of 3.5% from 2018 to 2022. This upward trajectory underscores the increasing recognition of the disease and the need for advanced therapeutic options.
Market Dynamics:
Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney condition that leads to scarring of the glomeruli, the filtering units within the kidneys. The increasing prevalence of FSGS globally is a major driver of market growth. However, as the condition is relatively rare, the therapeutics market remains niche, requiring continued innovation and investment in research and development.
Current treatment options include:
- Corticosteroids: Prednisone is widely used to reduce kidney inflammation and decrease proteinuria, a hallmark symptom of FSGS.
- Immunosuppressive Drugs: Medications like cyclosporine play a crucial role in controlling the immune system to mitigate kidney damage.
While these treatments are effective in managing symptoms and slowing disease progression, the market is ripe for the development of novel therapies that address unmet clinical needs.
Growth Opportunities:
Advancements in precision medicine and the introduction of targeted biologics are expected to further propel the market. Additionally, increased awareness among healthcare professionals and patients, combined with robust funding for research initiatives, is likely to unlock new avenues for growth in the FSGS therapeutics market.
Future Outlook:
“The significant growth trajectory of the FSGS therapeutics market highlights the urgent need for innovative solutions to combat this debilitating condition. With advancements in immunotherapy and the potential for gene-based therapies, the future looks promising for both patients and healthcare providers,” stated FMI.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market grew at a CAGR of 3.5%.
- The global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market is expected to grow with a 5% CAGR during 2023 to 2033.
- As of 2033, the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market is expected to reach US$ 4.89 Billion.
- According to the FMI analysis, the immunosuppressive agents segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Market Competition:
Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.
- In May 2022, Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review. Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.
The NDA submission for sparsentan is based on results from the ongoing Phase 3 PROTECT Study, which is one of the largest interventional studies conducted in IgAN to date. The study evaluated sparsentan in 404 patients with persistent proteinuria and met its pre-specified interim primary efficacy endpoint, which measured changes in proteinuria compared to the active control irbesartan.
Key Segments Profiled in the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Industry Survey:
Disease Type:
- Primary FSGS
- Secondary FSGS
Drug Class:
- Corticosteroids
- Immunosuppressive Drugs
- Plasmapheresis
- ACE Inhibitors and ARBs
- Diuretics
Treatment:
- Drug Therapy
- Dialysis
- Kidney Transplant
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube